Search Results - Edward M. Wolin

Refine Results
  1. 1
    Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung

    Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung by Edward M. Wolin

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors

    Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors by Edward M. Wolin, John Leyden, Grace Goldstein, Teodora Kolarova, Ron Hollander, Richard R.P. Warner

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Pharmacokinetic study of aldoxorubicin in patients with solid tumors

    Pharmacokinetic study of aldoxorubicin in patients with solid tumors by Monica Mita, Ronald B. Natale, Edward M. Wolin, Brenda Laabs, Hillary Dinh, Scott Wieland, Daniel Levitt, Alain C. Mita

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

    Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study by Martyn Caplin, Marianne Pavel, Alexandria T. Phan, Jarosław B. Ćwikła, Eva Sedláčková, Xuan-Mai Truong Thanh, Edward M. Wolin, Philippe Ruszniewski

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors

    Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors by Mohammadali Hamiditabar, Ali Muzammil, Joseph Roys, Edward M. Wolin, Thomas M. O’Dorisio, David Ranganathan, Izabela Tworowska, Jonathan Strosberg, Ebrahim S. Delpassand

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Impact of <sup>68</sup>Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

    Impact of <sup>68</sup>Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective by Ken Herrmann, Johannes Czernin, Edward M. Wolin, Pawan Gupta, Martin Barrio, Antonio Gutiérrez, Christiaan Schiepers, Sherly Mosessian, Michael E. Phelps, Martin Allen-Auerbach

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs

    Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs by Simron Singh, Donald Granberg, Edward M. Wolin, Richard R.P. Warner, Maia Sissons, Teodora Kolarova, Grace Goldstein, Marianne Pavel, Kjell Öberg, John Leyden

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors by Catherine Lombard‐Bohas, James C. Yao, Timothy J. Hobday, Eric Van Cutsem, Edward M. Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H. Shah, Jaume Capdevila, Rodney F. Pommier

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

    Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors by Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

    Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study by Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Edda Gomez-Panzani, Philippe Ruszniewski, _ _

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study

    Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study by Éric Baudin, J. Capdevila, Dieter Hörsch, Simron Singh, M. Caplin, Edward M. Wolin, Wieneke A. Buikhuisen, Markus Raderer, Éric Dansin, Christian Grohé, Diego Ferone, A Houchard, X.-M. Truong-Thanh, Diane Reidy‐Lagunes, NULL AUTHOR_ID

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial

    Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial by Jonathan Strosberg, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, Kjell Öberg, Maribel Lopera Sierra, Thomas Thevenet, Inés Margalet, Philippe Ruszniewski, Eric P. Krenning

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Consensus on biomarkers for neuroendocrine tumour disease

    Consensus on biomarkers for neuroendocrine tumour disease by Kjell Öberg, Irvin M. Modlin, Wouter W. de Herder, Marianne Pavel, David S. Klimstra, Andrea Frilling, David C. Metz, Anthony P. Heaney, Dik J. Kwekkeboom, Jonathan Strosberg, T Meyer, Steven F. Moss, Kay Washington, Edward M. Wolin, Eric Liu, James R. Goldenring

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

    Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: S... by James C. Yao, Katherine A. Guthrie, César A. Moran, Jonathan Strosberg, Matthew H. Kulke, Jennifer A. Chan, Noelle K. LoConte, Robert R. McWilliams, Edward M. Wolin, Bassam Mattar, Shannon McDonough, Helen Chen, Charles D. Blanke, Howard S. Höchster

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    Everolimus for Advanced Pancreatic Neuroendocrine Tumors by James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

    Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis by Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, Margot Tesselaar, Edward M. Wolin, Eric Van Cutsem, Paola Tomassetti, Jonathan Strosberg, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Antonia Ridolfi, Fabian Herbst, Jiří Tomášek, Simron Singh, Marianne Pavel, Matthew H. Kulke, Juan W. Valle, James C. Yao

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

    Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues by Edward M. Wolin, Barbara Jarząb, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David R. Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Li Jiang, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell‐Price, Wasat Mansoor, Kjell Öberg

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States

    Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States by Li Zhu, Laura H. Tang, Xinwei Qiao, Edward M. Wolin, Nicholas N. Nissen, Deepti Dhall, Jie Chen, Lin Shen, Yihebali Chi, Yaozong Yuan, Qiwen Ben, Bin Lv, Yaru Zhou, Chunmei Bai, Jie Chen, Yu‐Li Song, Tiantian Song, Chongmei Lu, Run Yu, Yuan‐Jia Chen

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

    Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary by Simron Singh, Carlo Carnaghi, Roberto Buzzoni, Rodney F. Pommier, Markus Raderer, Jiří Tomášek, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Edward M. Wolin, Natsuko Okita, Steven K. Libutti, Do‐Youn Oh, Matthew H. Kulke, Jonathan Strosberg, James C. Yao, Marianne Pavel, Nicola Fazio

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study by James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: